{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-072064","form_type":"8-K","ticker":"SRPT","cik":"0000873303","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.867335+00:00","generated_at":"2026-05-16T00:35:01.860798+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sarepta CEO Douglas Ingram to retire by end of 2026; successor search underway","bullets":["CEO Douglas Ingram notified retirement by end of 2026 or upon appointment of replacement.","Board has commenced search for successor, considering internal and external candidates.","Ingram will remain CEO until successor is appointed or through 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-072064","json":"https://secwatch.observer/filing/0001193125-26-072064.json","markdown":"https://secwatch.observer/filing/0001193125-26-072064.md","text":"https://secwatch.observer/filing/0001193125-26-072064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/873303/000119312526072064/0001193125-26-072064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/873303/000119312526072064/srpt-20260225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:35:01.860798+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}